News | December 16, 2009

University of Virginia Collaborates to Develop New Cardio Drugs

December 17, 2009 – The University of Virginia (UVa) in Charlottesville and AstraZeneca this week entered into a strategic research collaboration to enhance development of new treatments, primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

The collaborative preclinical research projects will focus on identifying disease mechanisms and biological targets that have the potential to be starting points for successful and commercially viable treatments of these diseases. The financial terms of the deal were not disclosed.

Atherosclerosis is one of the primary causes of heart diseases, stroke and often death in both men and women in western societies. All evidence suggests that this will increase further as risk factors such as poor diet, increased body weight, and a sedentary lifestyle all increase and the prevalence of obesity and diabetes mellitus reach epidemic proportions globally.

The traditional nonsurgical approach to managing CAD has been through treatment of risk factors such as dyslipidemia, hypertension, diabetes, obesity and others. New and innovative approaches, which act directly on the disease in the vessel wall to slow the progression of, regress, or stabilize the atherosclerotic plaque, could be important, especially when linked to novel biomarkers of vulnerable plaque.

“This is an area of high unmet medical need: atherosclerosis is a primary cause of cardiovascular morbidity and mortality,” said Bjorn Wallmark, vice president of cardiovascular and gastrointestinal research, AstraZeneca. “AstraZeneca is committed to finding innovative solutions. By partnering with the University of Virginia and working together on the complex biology of these diseases it increases the potential of delivering new treatment options.”

“We are very pleased to join AstraZeneca in advancing the science of cardiovascular research,” said Gary Owens, director of UVa’s Robert M. Berne Cardiovascular Research Center and UVa principal investigator of the AstraZeneca-UVa Alliance. “Our partnership has the potential to greatly speed up the development of novel drugs to treat diseases in several targeted areas, taking these projects years ahead in some cases.”

For more information: www.astrazeneca.com

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init